Account

Background Heartbeat

Medical Cannabis Monitoring: What Follow-Up Actually Involves

A doctor reviewing notes with a patient, the consultation where medical cannabis monitoring actually happens

Medical cannabis monitoring is the follow-up a prescriber builds around a cannabis medicine: scheduled reviews, a record of how symptoms and side effects are actually behaving, a check against everything else you take, and a route for reporting anything unexpected to SAHPRA. In South Africa it matters more than for most medicines, because cannabis products are generally unregistered and reach patients under a section 21 authorisation granted for one named person at a time. Nothing on this page is a dosing instruction. Dosing belongs to your prescriber.

Last updated:

Key takeaways

  • Monitoring is not an optional extra on this route. It is how an unregistered medicine is kept safe for one named patient.
  • Most section 21 authorisations are time limited, so a review is built into the route whether or not anything has gone wrong.
  • The most useful thing a patient brings to a review is a plain record of symptoms, sleep, side effects and timing.
  • Interaction checks matter here because cannabinoids are metabolised by the same liver enzymes as many common medicines.
  • Anything unexpected can be reported to SAHPRA, and reporting does not require certainty that the medicine caused it.

Monitoring only exists inside the prescribed route. If you are not on it yet, you can register for Professor Green store access and begin with a prescriber consultation.

What medical cannabis monitoring actually means here

Monitoring is the structured follow-up that sits between a first prescription and a repeat. It covers four things: whether the treatment is doing what it was prescribed for, whether it is causing problems, whether it still fits with everything else you take, and whether the authorisation and prescription behind it are still current.

The South African context changes the emphasis. Most cannabis medicines here are not registered with SAHPRA, so they are supplied under section 21, which authorises an unregistered medicine for a named patient. That authorisation is specific and time limited rather than open ended, which means a review is scheduled into the route by design.

The practical consequence is that medical cannabis monitoring is not something you have to ask for. It is the mechanism by which the next supply is justified at all, and a prescriber who is not reviewing you is not in a position to continue prescribing.

Before you start

In South Africa, medical cannabis containing THC is prescription only through a registered doctor, usually via a SAHPRA section 21 authorisation. This page is general information for adults 18 and over, not medical advice, and it contains no dosing guidance. Speak to your doctor or pharmacist before starting, stopping or changing any treatment, and never adjust a dose on the strength of an article.

What your prescriber is watching for

A review is not a formality, and it is more specific than asking whether you feel better. A prescriber is generally looking at the response against the reason for prescribing, at side effects, at anything that has changed in your other medicines, and at whether the original reasoning still holds.

Sedation, dry mouth, dizziness and changes in appetite are among the commonly reported effects of cannabinoid medicines, and a review is where those get weighed against the benefit rather than tolerated silently. Our guide to the side effects people actually report covers how often these turn up in the literature. Effects on mood, concentration or driving are also part of the picture, and section 65 of the National Road Traffic Act 93 of 1996 makes no exemption for a medicine that has been prescribed to you.

A patient writing in a notebook, the symptom record that makes medical cannabis monitoring useful at a review

What a patient should actually record

The single thing that makes a review productive is a record kept at the time rather than reconstructed in the waiting room. It does not need to be elaborate.

What to noteHow much detailWhy it helps at the review
SymptomsThe specific thing the medicine was prescribed for, rated the same way each timeLets your prescriber see a trend rather than a mood on the day
TimingWhen you took it and when any effect appeared or wore offSeparates a timing problem from a treatment problem
Side effectsWhat happened, when, and how long it lastedTurns a vague complaint into something that can be acted on
SleepHours and quality, if sleep is part of why you are being treatedOne of the first things to shift, in either direction
Other medicinesAnything new, including over the counter and herbal productsInteractions are the most common avoidable problem
Missed or changed dosesSimply that it happenedA treatment that is not being taken as prescribed is not a treatment that failed

None of that is a substitute for clinical judgement. It is the raw material clinical judgement needs, and without it a review becomes a conversation about impressions.

A record like this is only worth keeping if a prescriber is going to read it. Register for legal access to start with an assessment and a scheduled review.

Why interaction checks are central to medical cannabis monitoring

Cannabidiol and tetrahydrocannabinol are both metabolised by cytochrome P450 enzymes, the same family that handles a long list of commonly prescribed medicines. A 2024 review in Pharmaceuticals set out the clinically relevant interactions and the practical recommendations that follow from them, and the short version is that the risk is real, predictable and manageable when it is known about.

That is why a review asks about everything you take rather than everything you were prescribed. Over the counter medicines, supplements and herbal products all count, and so does anything a different doctor started since your last appointment. This is also the reason to use one dispensing pharmacy where you can, because a pharmacy holding your full record can see a conflict that no single prescriber would.

What you should not do is manage a suspected interaction yourself by skipping or halving something. Tell the prescriber or the pharmacist and let the adjustment be a clinical decision.

A pharmacist checking a dispensed medicine against its record before handover

Reporting something unexpected

SAHPRA maintains a safety reporting route for adverse events and product quality problems, and it is open to patients as well as health professionals. You do not need to be sure that the medicine caused what happened. A suspicion is the standard, which is the point of a reporting system: patterns only become visible once enough individually uncertain reports exist.

In practice, tell your prescriber and the dispensing pharmacy first, because they can act immediately and they are the people who will report it formally in most cases. For a product problem, such as packaging or labelling that looks wrong, the dispensing pharmacy is the right first call, and our guide to how cannabis quality control works covers what a batch record can and cannot tell you.

What monitoring cannot do

It cannot make a treatment work. Medical cannabis monitoring shows you what is happening and gives a prescriber a basis for continuing, adjusting or stopping, but the evidence base for cannabinoid medicines varies a great deal by condition. The 2017 National Academies review remains a useful map of where the evidence is stronger and where it is thin, and it does not support a claim that cannabis treats or cures a disease.

Where the evidence is comparatively better developed, as our guide to medical cannabis for chronic pain in South Africa sets out, monitoring is what turns that general picture into a decision about you. It also cannot substitute for the rest of your care. A cannabis medicine sits alongside whatever else is being done for the condition, and monitoring works best when the prescriber managing the condition knows about it. If that is a different doctor, say so.

How Professor Green fits into the process

Professor Green is not a prescriber, a pharmacy or a laboratory. It does not assess you, does not decide what is appropriate and does not monitor anyone. What it does is connect adults in South Africa with the registered prescriber route, so an assessment happens, a section 21 authorisation is applied for by the prescriber where the product is unregistered, and a licensed pharmacy dispenses against the prescription.

Named cultivars such as Caribbean Breeze are supplied only on that basis. The monitoring described here belongs to that prescriber and that pharmacy. Registering is a step towards an assessment and is not a guarantee of eligibility, of a prescription or of supply.

Medical cannabis monitoring: frequently asked questions

How often will I be reviewed?

That is set by your prescriber and by the authorisation behind your medicine. Section 21 authorisations are time limited, so a review is built into the route rather than being requested when something goes wrong.

What should I bring to a medical cannabis monitoring review?

A record kept at the time: symptoms rated consistently, timing, side effects, sleep if it is relevant, any new medicines or supplements, and any doses you missed or changed.

Are blood tests part of monitoring?

Sometimes, depending on your other conditions and medicines rather than on the cannabis itself. Whether any test is needed is a clinical decision for your prescriber.

Can I adjust my own dose between reviews?

No. Dosing is a clinical decision and changing it yourself removes the basis on which the medicine was authorised for you. Contact the prescriber or the dispensing pharmacy instead.

What if I am taking other medicines?

Tell your prescriber and your pharmacist about everything, including over the counter and herbal products. Cannabinoids are handled by the same liver enzymes as many common medicines, so interactions are a routine part of the check.

Who do I tell if I have a bad reaction?

Your prescriber and the dispensing pharmacy first. SAHPRA also accepts safety reports directly, and you do not need to be certain the medicine was the cause.

Does monitoring mean the medicine is risky?

It means it is unregistered and authorised for you specifically. Follow-up is how that authorisation is justified, not a sign that something is expected to go wrong.

Can I drive while on a prescribed cannabis medicine?

Section 65 of the National Road Traffic Act 93 of 1996 has no exemption for a prescribed medicine with a narcotic effect. Ask your prescriber directly about driving before you assume either way.

Sources and references

The bottom line on medical cannabis monitoring

Good medical cannabis monitoring is unglamorous. It is a scheduled review, an honest record, a full list of what else you take, and a clear route for saying that something unexpected happened. None of it is optional on a route built around an unregistered medicine authorised for one named person.

It is also the clearest practical difference between a prescribed medicine and anything bought outside that route. Nobody is monitoring an informal purchase, nobody is checking it against your other medicines, and there is nowhere to report it when something goes wrong.

Get legal medical cannabis access in South Africa

Professor Green connects you with the registered prescriber route, so an assessment, a section 21 authorisation where it is needed, a licensed pharmacy and a scheduled review all come with the medicine.

Register for legal access
Share the Post:

Related Posts

Professorgreen.co.za is ran by Green Tec LLC is an authorised marketing affiliate for the Dr Green network who holds the Medical Cannabis licences in South Africa. We do not sell, handle, or ship cannabis. All cannabis products are sold and fulfilled by licensed operator DR Green.

Our Social